These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38682280)

  • 1. Novel investigational drugs for alopecia areata and future perspectives.
    Chim I; Ghiya R; Sinclair RD; Eisman S
    Expert Opin Investig Drugs; 2024 May; 33(5):441-449. PubMed ID: 38682280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
    Eisman S; Sinclair R
    Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus kinase inhibitors for alopecia areata.
    King BA; Craiglow BG
    J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK inhibition in the treatment of alopecia areata - a promising new dawn?
    Ismail FF; Sinclair R
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):43-51. PubMed ID: 31865802
    [No Abstract]   [Full Text] [Related]  

  • 5. Emerging drugs for the treatment of alopecia areata.
    Ramírez-Marín HA; Tosti A
    Expert Opin Emerg Drugs; 2022 Dec; 27(4):379-387. PubMed ID: 36408593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs under investigation for the treatment of alopecias.
    Ocampo-Garza J; Griggs J; Tosti A
    Expert Opin Investig Drugs; 2019 Mar; 28(3):275-284. PubMed ID: 30642204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs for alopecia areata: JAK inhibitors.
    Iorizzo M; Tosti A
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):77-81. PubMed ID: 29466675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).
    King B; Senna MM; Mesinkovska NA; Lynde C; Zirwas M; Maari C; Prajapati VH; Sapra S; Brzewski P; Osman L; Hanna S; Wiseman MC; Hamilton C; Cassella J
    J Am Acad Dermatol; 2024 Nov; 91(5):880-888. PubMed ID: 39053611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis.
    Guan R; Lin Y; Zhang C; Wang Z; Wu Z; Liu X; Chen X; Piao Y
    Arch Dermatol Res; 2024 Jul; 316(7):483. PubMed ID: 39042154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
    Wei D; Chen Y; Shen Y; Xie B; Song X
    Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System.
    Song CJ; Riley CA; Wilkison BD; Cho S
    Mil Med; 2024 Jun; ():. PubMed ID: 38850223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors.
    Gupta AK; Wang T; Polla Ravi S; Bamimore MA; Piguet V; Tosti A
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):666-679. PubMed ID: 36478475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors.
    Paggioli I; Moss J
    J Autoimmun; 2022 Dec; 133():102926. PubMed ID: 36335798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.
    Papierzewska M; Waśkiel-Burnat A; Rudnicka L
    Clin Drug Investig; 2023 May; 43(5):325-334. PubMed ID: 37138134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
    Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
    J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase inhibitors for alopecia areata: A narrative review.
    Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
    Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
    Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
    J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
    Ramot Y; Zlotogorski A
    Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
    Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
    Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.